A blood test that identifies Alzheimer's disease has been developed by a team of researchers from the University of Pittsburgh, the Swedish University of Gothenburg and the Italian University of Brescia.
Their findings, published in the journal Brain, show that the new biomarker, based on an antibody that specifically binds to the protein tau produced in the brain, outperforms current tests used to detect neurodegeneration associated with Alzheimer's.
Currently, diagnosis requires a brain scan or analysis of cerebrospinal fluid, but "these tests are expensive and many patients do not have access to them," said Thomas Karikari, assistant professor of psychiatry at the University of Pittsburgh.
Therefore, there is a need to develop less invasive and cheaper tests.
Current blood-based diagnostic methods can already detect tau abnormalities present in plasma, but have difficulty detecting brain-specific markers, meaning they are not affected by tau proteins produced by non-brain cells.
The tests showed that the levels of BD-tau detected matched cerebrospinal fluid tau levels and reliably distinguished Alzheimer's from other neurodegenerative diseases.
They also correlated with the severity of amyloid plaques and tau tangles in brain tissue, confirmed by autopsy.
Scientists hope that the introduction of such tests can help identify and enroll patients in population groups so far excluded from research in clinical trials./ Ansa